Category

News
This article was originally published by Targeted Oncology. C. Ola Landgren, MD, PhD, chief of Myeloma Service and hematologic oncologist at Memorial Sloan Kettering Cancer Center, discusses the use of chimeric antigen receptor (CAR) T cells and CAR natural killer (NK) cells in the multiple myeloma setting. As with every therapy, there are pros and cons...
Continue Reading
Hamilton Myeloma Semimar, Saturday 5 September Come along to our Hamilton Myeloma Patient Seminar, hosted by MyelomaNew Zealand and Leukaemia & Blood Cancer New Zealand. During the morning, we will hear from Dr Henry Chan (Waitemata DHB) and Dr Hugh Goodman (Waikato DHB) who will discuss some of the changes to come in 2020 for...
Continue Reading
Blenrep, an antibody-drug conjugate, is the first drug approved for multiple myeloma that targets the antigen BCMA. Several other companies are also developing BCMA-targeting therapies for the blood cancer, including CAR-T cells and bispecific antibodies. The Food and Drug Administration has granted accelerated approval to a drug for multiple myeloma that is the first of...
Continue Reading
For many patients with multiple myeloma, a new generation of drugs and drug combinations is producing better outcomes and fewer side effects. In recent months, several novel therapies studied and tested by Dana-Farber scientists have gained approval from the U.S. Food and Drug Administration (FDA) or taken a step toward approval after posting solid results...
Continue Reading
This article was originally published by Cancer Therapy Advisor Researchers have used deep whole-genome sequencing (WGS) to identify genomic markers of a “good-risk” group of patients with multiple myeloma with prolonged survival. Specifically, patients found to have a low genomic scar score and chromosome 9 gain had superior outcomes. In the study, researchers analyzed WGS...
Continue Reading
This was originally published by AJMC Severe renal impairment (RI) is associated with decreased rates of survival among patients with multiple myeloma (MM), even if renal function is restored with therapy, according to new research. Investigators from Fujian Medical University Union Hospital in China found patients who achieved restoration of renal function recovery had somewhat better odds...
Continue Reading
This article was originally published by Cancer Therapy Advisor Receipt of dialysis may be a risk factor for inpatient mortality in patients with multiple myeloma (MM) being treated with high-dose melphalan and autologous stem cell transplantation (HDM-ASCT), according to study results published in the European Journal of Haematology. To evaluate inpatient mortality trends, investigators conducted a...
Continue Reading
This post was originally published by Myeloma Research News GlaxoSmithKline’s investigational therapy belantamab mafodotin has been recommended for approved in the European Union, by the Committee for Medicinal Products for Human Use (CHMP), for heavily treated multiple myeloma patients. The marketing authorization application, accepted for review in February, is specific for people with relapsed or refractory disease who were previously treated with an immunomodulatory agent, a proteasome inhibitor, and...
Continue Reading
An office of the U.S. Food and Drug Administration (FDA has recommended that belantamab mafodotin, GlaxoSmithKline’s investigational antibody-drug conjugate, be approved for heavily pretreated relapsed or refractory multiple myeloma patients. The recommendation by the FDA’s  Oncologic Drugs Advisory Committee is for patients who had at least four prior lines of treatment, including an immunomodulatory agent, a proteasome inhibitor,...
Continue Reading
Come along to our Whangarei Myeloma Patient Seminar, hosted by Myeloma New Zealand and Leukaemia & Blood cancer New Zealand. During the evening, we will hear from Ken Romeril (Myeloma NZ) and Dr Sarah Poplar (Northland DHB) who will discuss some of the changes to come in 2020 for Myeloma treatment. Wednesday 12 August5.30pm to...
Continue Reading
1 11 12 13 14 15 37

Floor 7, 90 The Terrace
Wellington Central
New Zealand